Worth Venture Partners LLC raised its holdings in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 362.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 906,557 shares of the company's stock after purchasing an additional 710,551 shares during the quarter. Worth Venture Partners LLC owned 3.75% of Theratechnologies worth $1,469,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of THTX. Wealthspire Advisors LLC bought a new position in Theratechnologies during the 4th quarter worth approximately $83,000. National Bank of Canada FI lifted its holdings in Theratechnologies by 65.4% during the 4th quarter. National Bank of Canada FI now owns 113,378 shares of the company's stock worth $191,000 after buying an additional 44,825 shares during the last quarter. Finally, Bare Financial Services Inc bought a new position in Theratechnologies during the 4th quarter worth approximately $39,000.
Theratechnologies Stock Down 5.3 %
NASDAQ:THTX traded down $0.07 during trading hours on Monday, reaching $1.25. 10,442 shares of the stock were exchanged, compared to its average volume of 54,850. The firm has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.51. Theratechnologies Inc. has a 52 week low of $0.88 and a 52 week high of $4.20. The stock has a market capitalization of $57.48 million, a P/E ratio of -2.13 and a beta of 1.41.
Theratechnologies (NASDAQ:THTX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $16.25 million during the quarter. As a group, analysts expect that Theratechnologies Inc. will post -0.03 earnings per share for the current year.
Theratechnologies Company Profile
(
Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Further Reading
Want to see what other hedge funds are holding THTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theratechnologies Inc. (NASDAQ:THTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
